BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 25429828)

  • 1. Prophylactic cervical lymph node irradiation provides no benefit for patients of stage IE extranodal natural killer/T cell lymphoma, nasal type.
    Wang L; Xia ZJ; Lu Y; Zhang YJ
    Med Oncol; 2015 Jan; 32(1):320. PubMed ID: 25429828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary site and regional lymph node involvement are independent prognostic factors for early-stage extranodal nasal-type natural killer/T cell lymphoma.
    Niu SQ; Yang Y; Li YY; Wen G; Wang L; Li ZM; Wang HY; Zhang LL; Xia YF; Zhang YJ
    Chin J Cancer; 2016 Apr; 35():34. PubMed ID: 27044275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD56-negative extranodal NK/T cell lymphoma should be regarded as a distinct subtype with poor prognosis.
    Wang L; Wang Z; Xia ZJ; Lu Y; Huang HQ; Zhang YJ
    Tumour Biol; 2015 Sep; 36(10):7717-23. PubMed ID: 25935537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type.
    Michot JM; Mazeron R; Danu A; Lazarovici J; Ghez D; Antosikova A; Willekens C; Chamseddine AN; Minard V; Dartigues P; Bosq J; Carde P; Koscielny S; De Botton S; Ferme C; Girinsky T; Ribrag V
    Eur J Cancer; 2015 Nov; 51(16):2386-95. PubMed ID: 26254810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma.
    Wang L; Wang ZH; Chen XQ; Li YJ; Wang KF; Xia YF; Xia ZJ
    Cancer; 2013 Jan; 119(2):348-55. PubMed ID: 22811078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer/T-cell lymphoma.
    Wei W; Wu P; Li L; Zhang ZH
    Hematology; 2017 Jul; 22(6):320-329. PubMed ID: 27917702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of chemoradiotherapy with radiotherapy alone for early-stage extranodal natural killer/T-cell lymphoma, nasal type in elderly patients.
    Su C; Nguyen KA; Bai HX; Balaji D; Cao Y; Karakousis G; Zhang PJ; Zhang G; Xiao R
    Leuk Lymphoma; 2018 Jun; 59(6):1406-1412. PubMed ID: 28980517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008).
    Yoon DH; Kim SJ; Jeong SH; Shin DY; Bae SH; Hong J; Park SK; Yhim HY; Yang DH; Lee H; Kang HJ; Lee MH; Eom HS; Kwak JY; Lee JH; Suh C; Kim WS
    Oncotarget; 2016 Dec; 7(51):85584-85591. PubMed ID: 27542213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Sandwich" Chemotherapy (CT) with Radiotherapy (RT) improves outcomes in patients with stage IE/IIE extranodal natural killer (NK)/T-cell Lymphomas.
    Zhang J; Zhu MY; Wang L; Wang H; Wang WD; Geng QR; Lu Y
    Asian Pac J Cancer Prev; 2013; 14(7):4061-6. PubMed ID: 23991953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent Chemoradiation Therapy Followed by Consolidation Chemotherapy for Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type.
    Oh D; Ahn YC; Kim SJ; Kim WS; Ko YH
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):677-83. PubMed ID: 26461010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy.
    Guo Y; Lu JJ; Ma X; Wang B; Hong X; Li X; Li J
    Oral Oncol; 2008 Jan; 44(1):23-30. PubMed ID: 17306611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of treatment modalities for nasal extranodal natural killer/T-cell lymphoma in early stages: The efficacy of CHOP regimen based concurrent chemoradiotherapy.
    Cao J; Lan S; Shen L; Si H; Zhang N; Li H; Guo R
    Oncotarget; 2017 Mar; 8(12):20362-20370. PubMed ID: 27901491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study.
    Kim SJ; Kim K; Kim BS; Kim CY; Suh C; Huh J; Lee SW; Kim JS; Cho J; Lee GW; Kang KM; Eom HS; Pyo HR; Ahn YC; Ko YH; Kim WS
    J Clin Oncol; 2009 Dec; 27(35):6027-32. PubMed ID: 19884539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiotherapy improves survival in early stage extranodal natural killer/T cell lymphoma patients receiving asparaginase-based chemotherapy.
    Li YY; Feng LL; Niu SQ; Wang HY; Zhang LL; Wang L; Xia ZJ; Huang HQ; Xia YF; Zhang YJ; Wang XC
    Oncotarget; 2017 Feb; 8(7):11480-11488. PubMed ID: 28002792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensity-modulated radiation therapy followed by GDP chemotherapy for newly diagnosed stage I/II extranodal natural killer/T cell lymphoma, nasal type.
    Huang Y; Yang J; Liu P; Zhou S; Gui L; He X; Qin Y; Zhang C; Yang S; Xing P; Sun Y; Shi Y
    Ann Hematol; 2017 Sep; 96(9):1477-1483. PubMed ID: 28695246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment outcomes of and prognostic factors for definitive radiotherapy with and without chemotherapy for Stage I/II nasal extranodal NK/T-cell lymphoma.
    Yang CW; Wang CW; Hong RL; Tsai CL; Yao M; Tang JL; Lin CW; Cheng AL; Kuo SH
    J Radiat Res; 2017 Jan; 58(1):114-122. PubMed ID: 27534792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211.
    Yamaguchi M; Tobinai K; Oguchi M; Ishizuka N; Kobayashi Y; Isobe Y; Ishizawa K; Maseki N; Itoh K; Usui N; Wasada I; Kinoshita T; Ohshima K; Matsuno Y; Terauchi T; Nawano S; Ishikura S; Kagami Y; Hotta T; Oshimi K
    J Clin Oncol; 2009 Nov; 27(33):5594-600. PubMed ID: 19805668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promising clinical outcomes of sequential and "Sandwich" chemotherapy and extended involved-field intensity-modulated radiotherapy in patients with stage I
    Wang HY; Niu SQ; Yang YY; Li YY; Chen HB; Zhang YJ
    Cancer Med; 2018 Dec; 7(12):5863-5869. PubMed ID: 30484966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-Course Versus Long-Course Chemoradiotherapy for Stage IE-IIE Extranodal Natural Killer/T cell Lymphoma, Nasal Type: A Multicenter Retrospective Study.
    Li J; Li Y; Zhong M; Liu X; Song Y; Li J; Li K; Yi P
    Med Sci Monit; 2018 May; 24():2683-2692. PubMed ID: 29712887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutaneous extranodal natural killer/T-cell lymphoma: a comparative clinicohistopathologic and survival outcome analysis of 45 cases according to the primary tumor site.
    Lee WJ; Jung JM; Won CH; Chang SE; Choi JH; Chan Moon K; Park CS; Huh J; Lee MW
    J Am Acad Dermatol; 2014 Jun; 70(6):1002-9. PubMed ID: 24629518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.